Key statistics
On Friday, Neurocrine Biosciences Inc (NB3:FRA) closed at 115.25, -20.65% below its 52-week high of 145.25, set on Feb 06, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 115.25 |
|---|---|
| High | 115.25 |
| Low | 115.25 |
| Bid | 119.35 |
| Offer | 119.60 |
| Previous close | 115.80 |
| Average volume | 29.70 |
|---|---|
| Shares outstanding | 99.71m |
| Free float | 98.23m |
| P/E (TTM) | 32.93 |
| Market cap | 13.75bn USD |
| EPS (TTM) | 4.19 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 07:07 GMT.
More ▼
Press releases
- Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
- Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results
- Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
- Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
- Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
- Neurocrine Biosciences to Host R&D Day on December 16
- Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
- Neurocrine Biosciences to Present at Upcoming Investor Conferences
- Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
More ▼
